Pancreatic Cancer Research

ResearcherUniversitat Pompeu FabraActive in the last 2 years

Cristina Fillat

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0801-3338; OpenAlex author ID A5066082571. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 17

  1. Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models. Last author DOI 10.1016/j.jconrel.2026.115320↗
  2. DYRK1A coordinates tumor–stroma secretory programs that promote an immunosuppressive microenvironment in pancreatic cancer Co-author DOI 10.1038/s41420-026-03444-w↗
  3. KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis. Last author DOI 10.1016/j.omton.2024.200928↗
  4. The LAMB3-EGFR signaling pathway mediates synergistic Anti-Cancer effects of berberine and emodin in Pancreatic cancer. Co-author DOI 10.1016/j.bcp.2024.116509↗
  5. Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/ph17070911↗
  6. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines11010119↗
  7. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ph15101199↗
  8. Inhibition of miR-222 by Oncolytic Adenovirus-Encoded miRNA Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models. Last author DOI 10.3390/cancers13133233↗
  9. MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics. Co-author DOI 10.1038/s41389-020-0227-y↗
  10. Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer. Last author DOI 10.1016/j.ymthe.2018.09.016↗
  11. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Last author DOI 10.1136/gutjnl-2018-316128↗
  12. Zeb1 in Stromal Myofibroblasts Promotes Kras-Driven Development of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-1882↗
  13. Deciphering microRNA targets in pancreatic cancer using miRComb R package. Co-author DOI 10.18632/oncotarget.24034↗
  14. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.10199↗
  15. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation. Last author DOI 10.1186/s12943-015-0413-2↗
  16. E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models. Last author DOI 10.1038/gt.2010.114↗
  17. Pancreatic cancer gene therapy: from molecular targets to delivery systems. Co-author DOI 10.3390/cancers3010368↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Silvia Pascual-Sabater · 5 shared papers, 2022–2026 · strength 1.25
  2. Caiming Xu · 4 shared papers, 2022–2024 · strength 0.92
  3. Ajay Goel · 4 shared papers, 2022–2024 · strength 0.92
  4. Marc Otero-Mateo · 3 shared papers, 2021–2026 · strength 0.73
  5. Haiyong Han · 3 shared papers, 2022–2024 · strength 0.61
  6. Giulia Raimondi · 4 shared papers, 2018–2021 · strength 0.50
  7. Susana de la Luna · 2 shared papers, 2019–2026 · strength 0.43
  8. Meritxell Gironella · 4 shared papers, 2018–2020 · strength 0.40
  9. Keisuke Okuno · 2 shared papers, 2022–2023 · strength 0.35
  10. Maria Rovira-Rigau · 3 shared papers, 2018–2020 · strength 0.30
  11. Yuan Li · 1 shared paper, 2024 · strength 0.26
  12. Elena Vila-Navarro · 2 shared papers, 2018–2020 · strength 0.20
  13. María Vila-Casadesús · 2 shared papers, 2018–2020 · strength 0.20
  14. Tetsuji Takayama · 1 shared paper, 2023 · strength 0.18
  15. Eva Cristina Vaquero · 2 shared papers, 2018–2019 · strength 0.17
  16. Elena Fernández-Castañer · 1 shared paper, 2020 · strength 0.11
  17. Philippe Soubeyran · 1 shared paper, 2020 · strength 0.11
  18. Juan Iovanna · 1 shared paper, 2020 · strength 0.11
  19. Jeroni Luna · 1 shared paper, 2019 · strength 0.09
  20. Luciano Sobrevals · 2 shared papers, 2011–2015 · strength 0.09
  21. María Victoria Maliandi · 2 shared papers, 2011–2015 · strength 0.09
  22. Irene Sangrador · 1 shared paper, 2018 · strength 0.08
  23. Carlos A. Orozco · 1 shared paper, 2016 · strength 0.05
  24. Judith Vinaixa · 1 shared paper, 2016 · strength 0.05
  25. Pedro Enrique Guerrero · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.